Moore Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Moore Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-70,000	Closed	-$7.2M	–	671
2023 Q2	$7.2M	Sell	70,000 -30,000	-30%	-$3.17M	0.12%	126
2023 Q1	$10.9M	Buy	100,000 +38,000	+61%	+$4.2M	0.23%	80
2022 Q4	$7.06M	Buy	+62,000	New	+$5.15M	0.17%	116
2021 Q1	–	Sell	-25,000	Closed	-$1.83M	–	924
2020 Q4	$1.83M	Hold	25,000	–	–	0.02%	363
2020 Q3	$1.94M	Buy	+25,000	New	+$1.72M	0.04%	269

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's HZNP Position: Q3 2023 in Review

Moore Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 70,000 shares — an estimated $7.2M sold.

Moore Capital Management first reported a position in HZNP in Q3 2020 and held it in 5 quarters. The position peaked at $10.9M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Moore Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Moore Capital Management sold 70,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $7.2M.
Moore Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 5 quarters.
Moore Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.9M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.